

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

NASYM lyophilisate and solvent for suspension for injection or nasal spray for cattle

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 2 ml contains:

### Active substance:

Live attenuated bovine respiratory syncytial virus (BRSV), strain Lym-56

$10^{4.7-6.5}$  CCID<sub>50</sub>\*

\*Cell culture infectious dose 50%

### Excipients:

Qualitative composition of excipients and other constituents
<b><u>Lyophilisate:</u></b>
Dextran
Sucrose
Gelatin
N-Z-amine
Sorbitol
Potassium dihydrogen phosphate
Dipotassium phosphate
<b><u>Solvent:</u></b>
Potassium dihydrogen phosphate
Disodium phosphate dodecahydrate
Sodium chloride
Potassium chloride
Water for injections

Lyophilisate: Whitish freeze-dried lyophilisate.

Solvent: Homogeneous clear solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Cattle.

### 3.2 Indications for use for each target species

Active immunisation of cattle to reduce virus shedding and respiratory clinical signs caused by bovine respiratory syncytial virus infection.

Onset of immunity: 21 days after administration of one dose by the nasal route.  
21 days after the second dose of the two-dose intramuscular vaccination schedule.

Duration of immunity: 2 months after nasal vaccination.  
6 months after intramuscular vaccination.

### 3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 3.4 Special warnings

Vaccinate healthy animals only.

### 3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Cattle:

Common (1 to 10 animals / 100 animals treated):	Slight alteration of faecal consistency
Uncommon (1 to 10 animals / 1 000 animals treated):	Elevated temperature <sup>1</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactic-type reaction <sup>2</sup>

<sup>1</sup>A peak in temperature of at least 1.7 °C two days after vaccination that resolves the next day without treatment.

<sup>2</sup>May be serious (including fatal). In case of such reactions, appropriate symptomatic treatment should be administered.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

### 3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

### 3.9 Administration routes and dosage

Nasal use or intramuscular use.

Reconstitute the vaccine with the corresponding volume of solvent:

Number of doses in vial of lyophilisate	Volume of solvent to be used
1 dose	2 ml
5 doses	10 ml
25 doses	50 ml

1. Peel the top off the aluminium cap on the vial containing the solvent and withdraw 10 ml (2 ml for the 1-dose vial).
2. Inject the solvent into the vial containing the lyophilisate (freeze-dried powder).
3. Shake until the freeze-dried powder is in suspension. The 1- and 5-dose vials are now ready to use.
4. For the 25-dose vial, once the freeze-dried powder is in suspension with the 10 ml of solvent, withdraw all the suspension obtained from the vaccine vial and inject it into the vial containing the remaining solvent.
5. Shake well before use. The reconstituted vaccine is a slightly yellowish homogeneous suspension.

Avoid contamination during reconstitution and use. Use only sterile needles and syringes for administration.

For nasal use, spray the required volume of the vaccine into the animal's nostrils (1 ml in each nostril) using an intranasal applicator (droplet size: 25–220 µm). It is recommended to use a new applicator for each animal.

The following doses and administration methods should be used:

#### **Cattle from 9 days of age**

Primary vaccination (nasal use): Spray 1 ml into each nostril (so the total volume administered is 2 ml).

Revaccination: One intramuscular injection of 2 ml should be given 2 months after the primary vaccination, and then every 6 months after the last revaccination.

#### **Cattle from 10 weeks of age**

Primary vaccination (intramuscular injection): One intramuscular injection of 2 ml should be given, followed by a second intramuscular injection of 2 ml given 4 weeks later.

Revaccination: One intramuscular injection of 2 ml should be given 6 months after completion of the primary vaccination scheme and then every 6 months after the last revaccination.

### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse reactions other than those described in section 3.6 occurred following the administration of an overdose.

**3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

**3.12 Withdrawal periods**

Zero days.

**4. IMMUNOLOGICAL INFORMATION**

**4.1 ATCvet code: QI02AD04.**

To stimulate active immunity against bovine respiratory syncytial virus.

Reduction of respiratory clinical signs (but not a reduction of virus shedding) is observed 5 days after nasal vaccination. Full immunity is established from 21 days after nasal vaccination.

**5. PHARMACEUTICAL PARTICULARS**

**5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product, except with the solvent supplied for use with the veterinary medicinal product.

**5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after reconstitution according to directions: use immediately.

Shelf life of the solvent: 5 years.

**5.3 Special precautions for storage**

Lyophilisate: Store and transport refrigerated (2 °C – 8 °C). Do not freeze. Protect from light.

Solvent: Store below 25 °C. Do not freeze. Protect from light.

**5.4 Nature and composition of immediate packaging**

Lyophilisate (vaccine): 3 or 10 ml type I glass vials of 1, 5 or 25 doses, sealed with a bromobutyl rubber stopper and aluminium cap.

Solvent: type I glass vials of 2 ml and polyethylene (PET) vials of 10 ml or 50 ml, sealed with a bromobutyl rubber stopper and aluminium cap.

Cardboard box with 1 lyophilisate vial of 5 doses and 1 vial of 10 ml of solvent.

Cardboard box with 1 lyophilisate vial of 25 doses and 1 vial of 50 ml of solvent.

Cardboard box with 10 lyophilisate vials of 5 doses.

Cardboard box with 10 vials of 10 ml of solvent.

Cardboard box with 10 lyophilisate vials of 25 doses.

Cardboard box with 10 vials of 50 ml of solvent.

Cardboard box with 10 lyophilisate vials of 1 dose and 10 vials of 2 ml of solvent.

Not all pack sizes may be marketed.

**5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.

**7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/19/241/001-005

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 29/07/2019

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{DD/MM/YYYY}

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**



## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box (1 x 5 doses and 1 x 25 doses)

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

NASYM lyophilisate and solvent for suspension for injection or nasal spray

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 2 ml contains:

Live attenuated bovine respiratory syncytial virus, strain Lym-56

$10^{4.7-6.5}$  CCID<sub>50</sub>\*

\*Cell culture infectious dose 50%

**3. PACKAGE SIZE**

1 vial of lyophilisate and 1 vial of solvent (5 doses)

1 vial of lyophilisate and 1 vial of solvent (25 doses)

**4. TARGET SPECIES**

Cattle.

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Nasal use or intramuscular use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Do not freeze.

Protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/19/241/001 (5 doses)

EU/2/19/241/002 (25 doses)

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box for lyophilisate (10 x 5 doses and 10 x 25 doses)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

NASYM lyophilisate for suspension for injection or nasal spray

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 2 ml contains:

Live attenuated bovine respiratory syncytial virus, strain Lym-56  $10^{4.7-6.5}$  CCID<sub>50</sub>\*

\*Cell culture infectious dose 50%

**3. PACKAGE SIZE**

10 vials of lyophilisate (50 doses)

10 vials of lyophilisate (250 doses)

**4. TARGET SPECIES**

Cattle.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Nasal use or intramuscular use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Do not freeze.

Protect from light.

<b>10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”</b>
--

Read the package leaflet before use.

<b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b>
--

For animal treatment only.

<b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b>
--

Keep out of the sight and reach of children.

<b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b>
---

LABORATORIOS HIPRA, S.A.

<b>14. MARKETING AUTHORISATION NUMBERS</b>
--

EU/2/19/241/003 (5 doses)

EU/2/19/241/004 (25 doses)

<b>15. BATCH NUMBER</b>
-------------------------

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box for lyophilisate and solvent (10 x 1 doses and 10 x 2 ml)

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

NASYM lyophilisate for suspension for injection or nasal spray  
Solvent for NASYM

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 2 ml contains:  
Live attenuated bovine respiratory syncytial virus, strain Lym-56  $10^{4.7-6.5}$  CCID<sub>50</sub>\*  
\*Cell culture infectious dose 50%

**3. PACKAGE SIZE**

10 vials of lyophilisate (10 doses) and 10 vials of solvent (20 ml).

**4. TARGET SPECIES**

Cattle.

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Nasal use or intramuscular use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}  
Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.  
Do not freeze.  
Protect from light.

<b>10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”</b>
--

Read the package leaflet before use.

<b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b>
--

For animal treatment only.

<b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b>
--

Keep out of the sight and reach of children.

<b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b>
---

LABORATORIOS HIPRA, S.A.

<b>14. MARKETING AUTHORISATION NUMBERS</b>
--

EU/2/19/241/005

<b>15. BATCH NUMBER</b>
-------------------------

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box for solvent (10 x 10 ml and 10 x 50 ml)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Solvent for NASYM

**2. STATEMENT OF ACTIVE SUBSTANCES**

**3. PACKAGE SIZE**

10 vials of solvent (100 ml)

10 vials of solvent (500 ml)

**4. TARGET SPECIES**

Cattle.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Nasal use or intramuscular use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.



<b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b>
--

For animal treatment only.

<b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b>
--

Keep out of the sight and reach of children.

<b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b>
---

LABORATORIOS HIPRA, S.A.

<b>14. MARKETING AUTHORISATION NUMBERS</b>
--

<b>15. BATCH NUMBER</b>
-------------------------

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****Vial of lyophilisate (1, 5 and 25 doses)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

NASYM

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Each dose of 2 ml contains:

Live attenuated bovine respiratory syncytial virus, strain Lym-56  $10^{4.7-6.5}$  CCID<sub>50</sub>**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**5. PACKAGE SIZE**

1 dose

5 doses

25 doses

<b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b>
---

Solvent vials (2, 10 and 50 ml)
---------------------------------

<b>1. NAME OF THE VETERINARY MEDICINAL PRODUCT</b>
--

Solvent for NASYM

<b>2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES</b>
---

<b>3. BATCH NUMBER</b>
------------------------

Lot {number}

<b>4. EXPIRY DATE</b>
-----------------------

Exp. {mm/yyyy}

<b>5. PACKAGE SIZE</b>
------------------------

2 ml  
10 ml  
50 ml

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

NASYM lyophilisate and solvent for suspension for injection or nasal spray for cattle

### 2. Composition

Each dose of 2 ml contains:

#### Active substance:

Live attenuated bovine respiratory syncytial virus, strain Lym-56 .....  $10^{4.7-6.5}$  CCID<sub>50</sub>\*

\*Cell culture infectious dose 50%

Lyophilisate: Whitish freeze-dried lyophilisate.

Solvent: Homogeneous clear solution.

### 3. Target species

Cattle.

### 4. Indications for use

Active immunisation of cattle to reduce virus shedding and respiratory clinical signs caused by bovine respiratory syncytial virus infection.

Onset of immunity: 21 days after administration of one dose by the nasal route.  
21 days after the second dose of the two-dose intramuscular vaccination schedule.

Duration of immunity: 2 months after nasal vaccination.  
6 months after intramuscular vaccination.

### 5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 6. Special warnings

#### Special warnings:

Vaccinate healthy animals only.

#### Special precautions for safe use in the target species:

Not applicable.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

Overdose:

No adverse reactions occurred following the administration of an overdose.

Major incompatibilities:

Do not mix with any other veterinary medicinal product, except with the solvent supplied for use with the veterinary medicinal product.

## **7. Adverse events**

Cattle:

Common (1 to 10 animals / 100 animals treated):
Slight alteration of faecal consistency
Uncommon (1 to 10 animals / 1 000 animals treated):
Elevated temperature <sup>1</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):
Anaphylactic-type (severe allergic) reaction <sup>2</sup>

<sup>1</sup>A peak in temperature of at least 1.7 °C two days after vaccination that resolves the next day without treatment.

<sup>2</sup> May be serious (including fatal). In case of such reactions, appropriate symptomatic treatment should be administered.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

## **8. Dosage for each species, routes and method of administration**

One dose is 2 ml.

Nasal use or intramuscular use.

The following doses and administration methods should be used:

### **Cattle from 9 days of age:**

Primary vaccination (nasal use): Spray 1 ml into each nostril (so the total volume administered is 2 ml).

Revaccination: One intramuscular injection of 2 ml should be given 2 months after the primary vaccination, and then every 6 months after the last revaccination.

### **Cattle from 10 weeks of age:**

Primary vaccination (intramuscular injection): One intramuscular injection of 2 ml should be given, followed by a second intramuscular injection of 2 ml given 4 weeks later.  
Revaccination: One intramuscular injection of 2 ml should be given 6 months after completion of the primary vaccination scheme and then every 6 months after the last revaccination.

## **9. Advice on correct administration**

Reconstitute the vaccine with the corresponding volume of solvent:

<b>Number of doses in vial of lyophilisate</b>	<b>Volume of solvent to be used</b>
1 dose	2 ml
5 doses	10 ml
25 doses	50 ml

1. Peel the top off the aluminium cap on the vial containing the solvent and withdraw 10 ml (2 ml for the 1-dose vial).
2. Inject the solvent into the vial containing the lyophilisate (freeze-dried powder).
3. Shake until the freeze-dried powder is in suspension. The 1- and 5-dose vials are now ready to use.
4. For the 25-dose vial, once the freeze-dried powder is in suspension with the 10 ml of solvent, withdraw all the suspension obtained from the vaccine vial and inject it into the vial containing the remaining solvent.
5. Shake well before use. The reconstituted vaccine is a slightly yellowish homogeneous suspension.

Avoid contamination during reconstitution and use. Use only sterile needles and syringes for administration.

For nasal use, spray the required volume of the vaccine into the animal's nostrils (1 ml in each nostril) using an intranasal applicator (droplet size: 25–220 µm). It is recommended to use a new applicator for each animal.

## **10. Withdrawal periods**

Zero days.

## **11. Special storage precautions**

Keep out of the sight and reach of children.  
Store and transport refrigerated (2 °C – 8 °C).  
Protect from light.

Do not use this veterinary medicinal product and the solvent after the expiry date which is stated on the carton and the label after Exp. The expiry date refers to the last day of that month.  
Shelf life after reconstitution according to directions: use immediately.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. Marketing authorisation numbers and pack sizes**

Marketing authorisation numbers: EU/2/19/241/001-005

Pack sizes:

Cardboard box with 1 lyophilisate vial of 5 doses and 1 vial of 10 ml of solvent.

Cardboard box with 1 lyophilisate vial of 25 doses and 1 vial of 50 ml of solvent.

Cardboard box with 10 lyophilisate vials of 5 doses.

Cardboard box with 10 vials of 10 ml of solvent.

Cardboard box with 10 lyophilisate vials of 25 doses.

Cardboard box with 10 vials of 50 ml of solvent.

Cardboard box with 10 lyophilisate vials of 1 dose and 10 vials of 2 ml of solvent.

Not all pack sizes may be marketed.

### **15. Date on which the package leaflet was last revised**

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

### **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

LABORATORIOS HIPRA, S.A.

Avda. la Selva, 135

17170 AMER (Girona) SPAIN

TEL: +34 972 43 06 60

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Local representatives and contact details to report suspected adverse reactions:

**België/Belgique/Belgien**

HIPRA BENELUX NV

Nieuwewandeling 62

9000 Gent

BELGIUM

Tel: +32 09 2964464

**Lietuva**

LABORATORIOS HIPRA, S.A.

Avda. La Selva 135

17170 Amer (Girona)

ISPANIJA

Tel: +34 972 43 06 60



**Република България**  
LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ИСПАНИЯ  
Тел: +34 972 43 06 60

**Česká republika**  
HIPRA SLOVENSKO, s.r.o.  
Zochova 5,  
811 03 Bratislava,  
SLOVENSKO  
Tel: +421 02 32 335 223

**Danmark**  
LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIEN  
Tel: +34 972 43 06 60

**Deutschland**  
HIPRA DEUTSCHLAND GmbH  
Am Wehrhahn 28-30  
40211 Düsseldorf  
DEUTSCHLAND  
Tel: +49 211 698236 – 0

**Eesti**  
LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
HISPAANIA  
Tel: +34 972 43 06 60

**Ελλάδα**  
HIPRA ΕΛΛΑΣ Α.Ε.  
Λεωφ. Αθηνών 80 & Μηριόνου 2-4,  
104 41 Κολωνός - ΑΘΗΝΑ - ΕΛΛΑΣ  
Τηλ: +30 210 4978660

**España**  
LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ESPAÑA  
Tel: +34 972 43 06 60

**France**  
HIPRA FRANCE  
7 rue Roland Garros, Batiment H  
44700 - Orvault -  
FRANCE  
Tél: +33 02 51 80 77 91

**Luxembourg/Luxemburg**  
HIPRA BENELUX NV  
Nieuwewandeling 62  
9000 Gent  
BELGIUM  
Tel: +32 09 2964464

**Magyarország**  
LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANYOLORSZÁG  
Tel: +34 972 43 06 60

**Malta**  
LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANJA  
Tel: +34 972 43 06 60

**Nederland**  
HIPRA BENELUX NV  
Nieuwewandeling 62  
9000 Gent  
BELGIUM  
Tel: +32 09 2964464

**Norge**  
LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIA  
Tlf: +34 972 43 06 60

**Österreich**  
HIPRA DEUTSCHLAND GmbH  
Am Wehrhahn 28-30  
40211 Düsseldorf  
DEUTSCHLAND  
Tel: +49 211 698236 – 0

**Polska**  
HIPRA POLSKA Sp.z.o.o.  
Ul. Wincentego Rzymowskiego 31  
02-697 Warszawa - POLSKA  
Tel: +48 22 642 33 06

**Portugal**  
ARBUSET, Produtos Farmacêuticos e Sanitários  
De Uso Animal, Lda  
Portela de Mafra e Fontainha - Abrunheira  
2665 – 191 Malveira - PORTUGAL  
Tel: +351 219 663 450

**Hrvatska**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ŠPANJOLSKA  
Tel: +34 972 43 06 60

**Ireland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPAIN  
Tel: +34 972 43 06 60

**Ísland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPÁNN  
Sími: +34 972 43 06 60

**Italia**

Hipra Italia S.r.l.  
Enrico Mattei, 2  
25030 Coccaglio (BS)  
ITALIA  
Tel: +39 030 7241821

**Κύπρος**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ΙΣΠΑΝΙΑ  
Τηλ: +34 972 43 06 60

**Latvija**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPĀNIJA  
Tel. +34 972 43 06 60

**România**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIA  
Tel: +34 972 43 06 60

**Slovenija**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ŠPANIJA  
Tel: +34 972 43 06 60

**Slovenská republika**

HIPRA SLOVENSKO, s.r.o.  
Zochova 5,  
811 03 Bratislava,  
SLOVENSKO  
Tel: +421 02 32 335 223

**Suomi/Finland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ESPANJA  
Puh/Tel: +34 972 43 06 60

**Sverige**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIEN  
Tel. +34 972 43 06 60

**United Kingdom (Northern Ireland)**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPAIN  
Tel: +34 972 43 06 60